Literature DB >> 26937615

The cellular origins of drug resistance in cancer.

Geoffrey R Oxnard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26937615     DOI： 10.1038/nm.4058

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

1.  High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

Authors:  Xin Ye; Zhong-Zheng Zhu; Lei Zhong; Yachao Lu; Yun Sun; Xiaolu Yin; Zhenfan Yang; Guanshan Zhu; Qunsheng Ji
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

2.  Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

Authors:  Erin M Tricker; Chunxiao Xu; Sharmeen Uddin; Marzia Capelletti; Dalia Ercan; Atsuko Ogino; Christine A Pratilas; Neal Rosen; Nathanael S Gray; Kwok-Kin Wong; Pasi A Jänne
Journal:  Cancer Discov       Date:  2015-06-02       Impact factor: 39.397

3.  Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors:  Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

4.  Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

Authors:  Maria E Arcila; Geoffrey R Oxnard; Khedoudja Nafa; Gregory J Riely; Stephen B Solomon; Maureen F Zakowski; Mark G Kris; William Pao; Vincent A Miller; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-01-19       Impact factor: 12.531

5.  Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Authors:  Geoffrey R Oxnard; Cloud P Paweletz; Yanan Kuang; Stacy L Mach; Allison O'Connell; Melissa M Messineo; Jason J Luke; Mohit Butaney; Paul Kirschmeier; David M Jackman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

6.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

7.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

8.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

9.  Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.

Authors:  Michael Ramirez; Satwik Rajaram; Robert J Steininger; Daria Osipchuk; Maike A Roth; Leanna S Morinishi; Louise Evans; Weiyue Ji; Chien-Hsiang Hsu; Kevin Thurley; Shuguang Wei; Anwu Zhou; Prasad R Koduru; Bruce A Posner; Lani F Wu; Steven J Altschuler
Journal:  Nat Commun       Date:  2016-02-19       Impact factor: 14.919

10.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Authors:  Aaron N Hata; Matthew J Niederst; Hannah L Archibald; Maria Gomez-Caraballo; Faria M Siddiqui; Hillary E Mulvey; Yosef E Maruvka; Fei Ji; Hyo-eun C Bhang; Viveksagar Krishnamurthy Radhakrishna; Giulia Siravegna; Haichuan Hu; Sana Raoof; Elizabeth Lockerman; Anuj Kalsy; Dana Lee; Celina L Keating; David A Ruddy; Leah J Damon; Adam S Crystal; Carlotta Costa; Zofia Piotrowska; Alberto Bardelli; Anthony J Iafrate; Ruslan I Sadreyev; Frank Stegmeier; Gad Getz; Lecia V Sequist; Anthony C Faber; Jeffrey A Engelman
Journal:  Nat Med       Date:  2016-02-01       Impact factor: 53.440
View more
  30 in total

1.  Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance.

Authors:  Judith Pérez-Velázquez; Jana L Gevertz; Aleksandra Karolak; Katarzyna A Rejniak
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

2.  Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?

Authors:  Michael L Cheng; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2018-09-06       Impact factor: 12.531

3.  Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

Authors:  S A Laurie; S Banerji; N Blais; S Brule; P K Cheema; P Cheung; N Daaboul; D Hao; V Hirsh; R Juergens; J Laskin; N Leighl; R MacRae; G Nicholas; D Roberge; J Rothenstein; D J Stewart; M S Tsao
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

Review 4.  Overcoming therapy resistance in EGFR-mutant lung cancer.

Authors:  Pasi A Jänne; Tony Mok; Solange Peters; Antonio Passaro
Journal:  Nat Cancer       Date:  2021-04-15

5.  Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses.

Authors:  Sheng-Fang Su; Chia-Hsin Liu; Chiou-Ling Cheng; Chao-Chi Ho; Tsung-Ying Yang; Kun-Chieh Chen; Kuo-Hsuan Hsu; Jeng-Sen Tseng; Huei-Wen Chen; Gee-Chen Chang; Sung-Liang Yu; Ker-Chau Li
Journal:  JCO Precis Oncol       Date:  2021-02-19

6.  Montelukast ameliorated pemetrexed-induced cytotoxicity in hepatocytes by mitigating endoplasmic reticulum (ER) stress and nucleotide oligomerization domain-like receptor protein 3 (NLRP3) activation.

Authors:  Zhengdong Fei; Lu Zhang; Lei Wang; Hui Jiang; Aiqin Peng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

Review 7.  Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.

Authors:  Emna Mahfoudhi; Charles Ricordel; Gwendoline Lecuyer; Cécile Mouric; Hervé Lena; Rémy Pedeux
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

Review 8.  Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jih-Hsiang Lee; James Chih-Hsin Yang
Journal:  J Biomed Sci       Date:  2016-12-03       Impact factor: 8.410

9.  Key Difficulties Associated with Cancer Biology.

Authors:  Xiaolan Fang; Jeanny Aragon-Ching; Esther Una Cidon
Journal:  Clin Med Insights Oncol       Date:  2016-11-15

10.  Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.

Authors:  Nicoletta Ferrari; Ilaria Granata; Matteo Capaia; Marina Piccirillo; Mario Rosario Guarracino; Roberta Venè; Antonella Brizzolara; Andrea Petretto; Elvira Inglese; Martina Morini; Simonetta Astigiano; Adriana Agnese Amaro; Francesco Boccardo; Cecilia Balbi; Paola Barboro
Journal:  Cell Commun Signal       Date:  2017-12-08       Impact factor: 5.712
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.